denis Moro-Sibilot (@dmslung) 's Twitter Profile
denis Moro-Sibilot

@dmslung

Professor of Respiratory Medicine, CHU Grenoble-Alpes. Honorary president IFCT Intergroupe Francophone de Cancérologie Thoracique. My opinions are my own.

ID: 1272759720

linkhttps://orcid.org/0000-0001-6776-8610 calendar_today16-03-2013 16:45:21

4,4K Tweet

1,1K Followers

337 Following

Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

The phase III ETOP 25-23 ADOPT-lung will try to determine the benefit of adjuvant immunotherapy after neoadjuvant chemo-IO, outlined in Lung Cancer Journal. Pts with resectable stage IIA-IIIB NSCLC receive induction durvalumab + chemo, then randomized to 1y of durva vs observation.

The phase III ETOP 25-23 ADOPT-lung will try to determine the benefit of adjuvant immunotherapy after neoadjuvant chemo-IO, outlined in <a href="/LungCaJournal/">Lung Cancer Journal</a>. Pts with resectable stage IIA-IIIB NSCLC receive induction durvalumab + chemo, then randomized to 1y of durva vs observation.
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

FDA grants breakthrough designation to YL201 for #SCLC. YL201 is a B7-H3 directed ADC with a proprietary topoisomerase-1 inhibitor payload. Looking forward to more data from the ongoing trials. medilinkthera.com/news-details/48

FDA grants breakthrough designation to YL201 for #SCLC. YL201 is a B7-H3 directed ADC with a proprietary topoisomerase-1 inhibitor payload. Looking forward to more data from the ongoing trials.

medilinkthera.com/news-details/48
Dr. Saadvik Raghuram y (@saadvikdr) 's Twitter Profile Photo

🚨FDA approves Talectrectinib for ROS1 positive locally advanced or metastatic NSCLC. ➡️ Response rates in TKI naive (85-90%) ➡️ ORR in patients with prior TKI (52%) ➡️ CNS response rates in TKI Naive (73%), prior TKI (63%) ➡️ Watch out for Dizziness, QTc OncoAlert Dr Amol Akhade

🚨FDA approves Talectrectinib for ROS1 positive locally advanced or metastatic NSCLC.

➡️ Response rates in TKI naive (85-90%)
➡️ ORR in patients with prior TKI (52%)
➡️ CNS response rates in TKI Naive (73%), prior TKI (63%)
➡️ Watch out for Dizziness, QTc
<a href="/OncoAlert/">OncoAlert</a>
<a href="/SuyogCancer/">Dr Amol Akhade</a>
Lung Cancer Europe (@lungcancereu) 's Twitter Profile Photo

🇩🇪 Germany confirms nationwide #lungcancer screening from Apr ‘26 - CT scans for high-risk groups, covered by statutory health insurance. - Huge EU system steps in - could spark action elsewhere - Access still hugely unequal across Europe - Took legal & radiation safety updates

🇩🇪 Germany confirms nationwide #lungcancer screening from Apr ‘26 - CT scans for high-risk groups, covered by statutory health insurance.

- Huge EU system steps in - could spark action elsewhere
- Access still hugely unequal across Europe
- Took legal &amp; radiation safety updates
Olivier Leleu (@leleuolivier80) 's Twitter Profile Photo

Bel article dans NEJM mettant en valeur le travail des pneumologues des hôpitaux généraux en France et qui conclut à une amelioration de la survie médiane des patients avec cancer du poumon passant de 8,5 mois en 2000 à 20,7 mois en 2020 ! #CPHG #KBP2020

IFCT lung (@ifctlung) 's Twitter Profile Photo

💡First patient treated by #ivonescimab at CHU de Montpellier in the IFCT-2403 BI-MAPS academic trial dedicated to pleural #mesothelioma @ponstostivint Scherpereel Arnaud iMig 2025 ifct.fr/etudes-cliniqu…

Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

Analysis of MARIPOSA JTO & JTO CRR comparing 1L lazertinib and osimertinib in #EGFR NSCLC. PFS 18.5m with lazertinib vs 16.6m with osimertinib (HR 0.98), RR 83% vs 85%, DOR 16.6m vs 16.8m, OS HR 1.00 - similar tox (laz more rash, osi more diarrhea). jto.org/article/S1556-…

Roberto Ferrara (@robertoferrara_) 's Twitter Profile Photo

❄️Winter of cancer immunotherapy is here. 𝐀𝐥𝐥-𝐜𝐨𝐦𝐞𝐫𝐬 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 & 𝐍𝐞𝐭𝐰𝐨𝐫𝐤-𝐞𝐟𝐟𝐞𝐜𝐭 slowed progress-we’ve hit a plateau. Time to prioritize innovation over convention! Editorial out in JTO & JTO CRR bit.ly/4eEVcv4 Fabio Salomone Antonio Nuccio

❄️Winter of cancer immunotherapy is here. 𝐀𝐥𝐥-𝐜𝐨𝐦𝐞𝐫𝐬 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 &amp; 𝐍𝐞𝐭𝐰𝐨𝐫𝐤-𝐞𝐟𝐟𝐞𝐜𝐭 slowed progress-we’ve hit a plateau. 
Time to prioritize innovation over convention!
Editorial out in <a href="/JTOonline/">JTO & JTO CRR</a> bit.ly/4eEVcv4
<a href="/FabioSalomone22/">Fabio Salomone</a> <a href="/AntonioNuccio01/">Antonio Nuccio</a>
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

David Gandara Agree - more similar than different. Slightly different toxicity profile and may vary at an individual patient level. But no meaningful differences in efficacy in my opinion. But I do think that Coke >>> Pepsi...

Diego A. Díaz García (@diegoadiazg) 's Twitter Profile Photo

🕐 OS according to time-of-day of combined IO-Ct: a bicentric bicontinental study. In advanced NSCLC, patients receiving immuno-chemotherapy before 11:30 a.m. had longer overall survival (33 vs 19.5 months). Real-world data from France & China point to a potential role for

🕐 OS according to time-of-day of combined IO-Ct: a bicentric bicontinental study.

In advanced NSCLC, patients receiving immuno-chemotherapy before 11:30 a.m. had longer overall survival (33 vs 19.5 months).

Real-world data from France &amp; China point to a potential role for
Dr. Yannick Neuder (@yannickneuder) 's Twitter Profile Photo

💡Je propose un « devoir de vacances » citoyen aux Français qui le peuvent : installez votre Carte Vitale numérique et le service « Mon espace santé » sur votre téléphone ! 😉 📱 Mon espace santé et la carte vitale numérique vous permettent de retrouver instantanément vos

Journal of Clinical Oncology (@jco_asco) 's Twitter Profile Photo

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. Co-authored by @conorsteuermd Read the full article. brnw.ch/21wU4uz

IFCT lung (@ifctlung) 's Twitter Profile Photo

Félicitations au Pr Alexis Cortot Alexis_Cortot , élu Président de l'IFCT (2025-2027), ainsi qu'aux membres élus au Conseil d'Administration de l'IFCT. Merci au Pr Westeel & aux membres sortants pour leur implication dans l’essor de notre intergroupe : ifct.fr/component/acym…

Félicitations au Pr Alexis Cortot <a href="/Cortot_Lille/">Alexis_Cortot</a> , élu Président de l'IFCT (2025-2027), ainsi qu'aux membres élus au Conseil d'Administration de l'IFCT. Merci au Pr Westeel &amp; aux membres sortants pour leur implication dans l’essor de notre intergroupe : ifct.fr/component/acym…
Dr Riyaz Shah (@drriyazshah) 's Twitter Profile Photo

Very important adjustment to FLAURA2 reimbursement in NHS England ; allowing early initiation of TKI while the chemo gets set up. Brilliant initiative by the cancer drugs fund team. BTOG #EGFR EGFR Positive Lung Cancer UK

Very important adjustment to FLAURA2 reimbursement in <a href="/NHSEngland/">NHS England</a> ; allowing early initiation of TKI while the chemo gets set up. Brilliant initiative by the cancer drugs fund team. <a href="/BTOGORG/">BTOG</a> #EGFR <a href="/EgfrUk/">EGFR Positive Lung Cancer UK</a>
d.planchard (@dplanchard) 's Twitter Profile Photo

What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer

What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer
Yakup Ergün (@dr_yakupergun) 's Twitter Profile Photo

There is no benefit of mediastinal lymph node dissection for ground-glass opacity–dominant T1N0M0 lung adenocarcinoma! (consolidation-to-tumor ratio ≤0.5 and total size ≤3 cm) A well-designed study supporting surgical de-escalation👇 ascopubs.org/doi/10.1200/JC…

There is no benefit of mediastinal lymph node dissection for ground-glass opacity–dominant T1N0M0 lung adenocarcinoma!

(consolidation-to-tumor ratio ≤0.5 and total size ≤3 cm)

A well-designed study supporting surgical de-escalation👇

ascopubs.org/doi/10.1200/JC…
Mike Thompson, MD, PhD, FASCO (@mtmdphd) 's Twitter Profile Photo

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] Ben Westphalen et al. npj Journals Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of >295,000 cancer patients

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] <a href="/BenWestphalen/">Ben Westphalen</a> et al. <a href="/Nature_NPJ/">npj Journals</a> Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of &gt;295,000 cancer patients